Bärtsch, M., Schlenzka, J., Mai, E. K., Merz, M., Hillengaß, J., Raab, M., . . . Goldschmidt, H. (2016). Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: A randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. BioMed Central; Springer.
Chicago-Zitierstil (17. Ausg.)Bärtsch, Marc-Andrea, et al. Rationale and Design of the German-Speaking Myeloma Multicenter Group (GMMG) Trial ReLApsE: A Randomized, Open, Multicenter Phase III Trial of Lenalidomide/dexamethasone Versus Lenalidomide/dexamethasone Plus Subsequent Autologous Stem Cell Transplantation and Lenalidomide Maintenance in Patients with Relapsed Multiple Myeloma. London; Berlin; Heidelberg: BioMed Central; Springer, 2016.
MLA-Zitierstil (9. Ausg.)Bärtsch, Marc-Andrea, et al. Rationale and Design of the German-Speaking Myeloma Multicenter Group (GMMG) Trial ReLApsE: A Randomized, Open, Multicenter Phase III Trial of Lenalidomide/dexamethasone Versus Lenalidomide/dexamethasone Plus Subsequent Autologous Stem Cell Transplantation and Lenalidomide Maintenance in Patients with Relapsed Multiple Myeloma. BioMed Central; Springer, 2016.